Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 17/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 15/20 | 0.45 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.41 |
| ▸ | CDK1 | P06493 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29574455 | 0.90 | ADORA3 (0.55) | ADORA3ADORA2AADORA1TMIGD3HTR2C | |
| SCHEMBL29574430 | 0.88 | ADORA3 (0.54) | ADORA3ADORA2AADORA1TMIGD3CDK1 | |
| SCHEMBL29573594 | 0.83 | ADORA3 (0.44) | ADORA3ADORA2AADORA1 | |
| SCHEMBL29574451 | 0.81 | ADORA3 (0.36) | ADORA3ADORA2AADORA1TMIGD3HTR2C | |
| SCHEMBL29574441 | 0.80 | ADORA3 (0.41) | ADORA3ADORA2AADORA1 | |
| SCHEMBL29573618 | 0.80 | ADORA3 (0.39) | ADORA3ADORA2AADORA1TMIGD3HTR2C | |
| SCHEMBL29573460 | 0.80 | ADORA3 (0.39) | ADORA3ADORA2AADORA1TMIGD3HTR2C | |
| SCHEMBL30480263 | 0.80 | ADORA3 (0.48) | ADORA3ADORA2AADORA1 | |
| SCHEMBL22757377 | 0.79 | ADORA3 (0.58) | ADORA3ADORA2AADORA1TMIGD3 | |
| SCHEMBL22757388 | 0.79 | PI4KA (0.53) | ADORA3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4196219-A1 | A3 ADENOSINE RECEPTOR AGONISTS FOR USE IN MEDICINE | Biointervene, Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022040241-A1 | A3 ADENOSINE RECEPTOR AGONISTS FOR USE IN MEDICINE | BIOINTERVENE, INC. (US) | 2022-02-24 | — | — | WO | disclosed |